Shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) have been assigned an average rating of “Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.33.
Several research analysts have recently weighed in on AUTL shares. William Blair reiterated a “buy” rating on shares of Autolus Therapeutics in a research note on Thursday, June 25th. BidaskClub cut shares of Autolus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Autolus Therapeutics in a research note on Friday, June 26th. Mizuho reiterated a “buy” rating and set a $24.00 price target on shares of Autolus Therapeutics in a research note on Thursday, August 6th. Finally, Needham & Company LLC started coverage on shares of Autolus Therapeutics in a research report on Monday, June 1st. They set a “buy” rating and a $26.00 price objective on the stock.
AUTL stock traded down $0.49 on Tuesday, hitting $12.36. The company had a trading volume of 106,400 shares, compared to its average volume of 142,241. Autolus Therapeutics has a 12-month low of $3.00 and a 12-month high of $17.19. The company has a current ratio of 9.12, a quick ratio of 9.12 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $15.06 and its 200 day simple moving average is $11.51. The stock has a market cap of $555.99 million, a price-to-earnings ratio of -4.48 and a beta of 1.96.
Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.09. Autolus Therapeutics had a negative net margin of 10,518.19% and a negative return on equity of 48.60%. Research analysts forecast that Autolus Therapeutics will post -2.63 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in AUTL. Jane Street Group LLC bought a new stake in Autolus Therapeutics in the 2nd quarter valued at $218,000. Opaleye Management Inc. bought a new stake in Autolus Therapeutics in the 2nd quarter valued at $962,000. California Public Employees Retirement System increased its holdings in Autolus Therapeutics by 289.0% in the 2nd quarter. California Public Employees Retirement System now owns 40,200 shares of the company’s stock valued at $644,000 after acquiring an additional 29,867 shares during the last quarter. Trexquant Investment LP bought a new stake in Autolus Therapeutics in the 2nd quarter valued at $708,000. Finally, New York State Common Retirement Fund increased its holdings in Autolus Therapeutics by 15.3% in the 2nd quarter. New York State Common Retirement Fund now owns 27,923 shares of the company’s stock valued at $448,000 after acquiring an additional 3,700 shares during the last quarter. Hedge funds and other institutional investors own 30.30% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Read More: 52- Week Highs
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.